{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:43Z","timestamp":1785517183062,"version":"3.56.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"DOI":"10.1007\/s10096-026-05609-y","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:11:51Z","timestamp":1785161511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence, risk factors, clinical characteristics and outcomes of tuberculosis-associated immune reconstitution inflammatory syndrome in a HIV and tuberculosis low-incidence setting"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-436X","authenticated-orcid":false,"given":"Chiara","family":"Sepulcri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Crupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"6","key":"5609_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2217\/fmb.15.9","volume":"10","author":"E Namale, Phiona","year":"2015","unstructured":"Namale, Phiona E et al (2015) Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol vol 10(6):1077\u20131099","journal-title":"Future Microbiol vol"},{"key":"5609_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jctube.2016.03.002","volume":"3","author":"M Lanzafame","year":"2016","unstructured":"Lanzafame M, Vento S (2016) Tuberculosis-immune reconstitution inflammatory syndrome. J Clin Tuberc Other Mycobact Dis 3:6\u20139","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"5609_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","volume":"365","author":"F-X Blanc","year":"2011","unstructured":"Blanc F-X et al (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New Engl J Med vol 365:1471\u20131481","journal-title":"New Engl J Med vol"},{"issue":"3","key":"5609_CR4","doi-asserted-by":"publisher","first-page":"ofae035","DOI":"10.1093\/ofid\/ofae035","volume":"11","author":"LE Coelho","year":"2024","unstructured":"Coelho LE et al (2024) Incidence and predictors of tuberculosis-associated IRIS in people with HIV treated for tuberculosis: findings from reflate TB2 randomized trial. Open forum Infect Dis 11(3):ofae035","journal-title":"Open forum Infect Dis"},{"key":"5609_CR5","doi-asserted-by":"crossref","unstructured":"Zhao Y et al (1999) Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomized trials. Journal of acquired immune deficiency syndromes 90,2(2022):232\u2013239","DOI":"10.1097\/QAI.0000000000002937"},{"issue":"8","key":"5609_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1473-3099(08)70184-1","volume":"8","author":"G Meintjes","year":"2008","unstructured":"Meintjes G et al (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis vol 8(8):516\u2013523","journal-title":"Lancet Infect Dis vol"},{"issue":"4","key":"5609_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ccm.2009.08.013","volume":"30","author":"G Meintjes","year":"2009","unstructured":"Meintjes G, Rabie H, Wilkinson RJ, Cotton MF (2009) Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med 30(4):797\u2013x","journal-title":"Clin Chest Med"},{"key":"5609_CR8","volume-title":"Module 5: management of tuberculosis in children and adolescents","author":"WHO operational handbook on tuberculosis","year":"2022","unstructured":"WHO operational handbook on tuberculosis (2022) Module 5: management of tuberculosis in children and adolescents. World Health Organization, Geneva. Licence: CC BY-NC-SA 3.0IGO"},{"issue":"1","key":"5609_CR9","doi-asserted-by":"publisher","first-page":"00108","DOI":"10.1183\/23120541.00108-2017","volume":"4","author":"Riccardi","year":"2018","unstructured":"Riccardi, Niccol\u00f2 et al (2018) Time to change the single-centre approach to management of patients with tuberculosis: a novel network platform with automatic data import and data sharing. ERJ open Res 4(1):00108\u20132017","journal-title":"ERJ open Res"},{"key":"5609_CR10","unstructured":"https:\/\/www.epicentro.iss.it\/tubercolosi\/hiv-tb , Accessed 24 June 2026"},{"issue":"5","key":"5609_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/QAI.0000000000002606","volume":"86","author":"C Stek","year":"2021","unstructured":"Stek C, Buyze J, Menten J et al (2021) Diagnostic accuracy of the INSHI consensus case definition for the diagnosis of paradoxical tuberculosis-IRIS. J Acquir Immune Defic Syndr 86(5):587\u2013592","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"5609_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.semdp.2017.04.010","volume":"34","author":"AM Nelson","year":"2017","unstructured":"Nelson AM et al (2017) Immune reconstitution inflammatory syndrome (IRIS): What pathologists should know. Seminars Diagn Pathol vol 34(4):340\u2013351","journal-title":"Seminars Diagn Pathol vol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05609-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05609-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05609-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:06:43Z","timestamp":1785514003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05609-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":12,"alternative-id":["5609"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05609-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Outside the submitted work, MB has received funding for scientific advisory boards, travel, and speaker honoraria from Angelini, Astellas, BioM\u00e9rieux, Cidara, Gilead, Menarini, MSD, Pfizer, Shionogi, Tetraphase, Nabriva, A.D.B. received funding for scientific advisory boards, travel, and speaker honoraria from ViiV Healthcare, Gilead, , L.T. attended advisory boards or served as consultant or received grants for conference participations from Gilead Sciences and ViiV Healthcare, and Janssen. The other authors have no conflicts of interests to disclose.","order":1,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}